Navigation Links
Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Date:11/29/2007

months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

About VYVANSE

Tell the doctor about any heart conditions, including structural abnormalities, that you, your child, or a family member, may have. Inform the doctor immediately if your child develops symptoms that suggest heart problems, such as chest pain or fainting.

VYVANSE should not be taken if your child has advanced disease of the blood vessels (arteriosclerosis); symptomatic heart disease; moderate to severe high blood pressure; overactive thyroid gland (hyperthyroidism); known allergy or unusual reactions to drugs called sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.

Tell the doctor before taking VYVANSE if your child is being treated for or has symptoms of depression (sadness, worthlessness, or hopelessness) or bipolar disorder; has abnormal thought or visions, hears abnormal sounds, or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell the doctor immediately if your child develops any of these conditions or symptoms while taking VYVANSE.

Abuse of amphetamines may lead to dependence. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use.

VYVANSE was generally well tolerated in clinical studies. The most common side effects reported in studies of
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... -- Symbiotix Biotherapies, Inc. ("Symbiotix") today announced that it ... Technology Transfer (STTR) Program award from the National Institutes ... Diseases (NIAID). The company, based in Boston ... molecular therapeutics from the human microbiome . ... the first molecule to emerge from the microbiome and ...
(Date:6/1/2015)... 2015  Elusys Therapeutics, Inc. (Elusys) today announced ... accepted for filing and review its Biologics License ... and prevention of inhalational anthrax, a top bioterror ... Anthim is a candidate for future acquisition into ... of critical medical supplies for biowarfare preparedness. Anthim ...
(Date:6/1/2015)... , June 1, 2015  MicroVention, Inc., a wholly ... company, announced today that it will build its new ... in Aliso Viejo, CA , the ... A groundbreaking ceremony to commemorate the start of ... 4, 2015 on the site where the new headquarters ...
Breaking Medicine Technology:Symbiotix Biotherapies Announces $2.3 Million Award from NIH's National Institute of Allergy and Infectious Diseases (NIAID) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 3MicroVention to Locate Its New 205,000 Square-Foot Worldwide Headquarters At Summit Office Campus in Aliso Viejo 2MicroVention to Locate Its New 205,000 Square-Foot Worldwide Headquarters At Summit Office Campus in Aliso Viejo 3
... FARMINGTON, Conn., May 9, 2012 /PRNewswire-iReach/ -- ... new reports tracking the growth in the patient monitoring ... Devices, Players, Markets and Forecasts The convergence of ... initiatives is driving patient monitoring away from caregiver facilities ...
... Medical Outsourcing announced today that the company hired ... As a seasoned quality specialist with 18 years ... the quality systems for all of Millstone Medical,s ... with customers to ensure the highest quality standards. ...
Cached Medicine Technology:New Forecast Shows Patient Monitoring Systems Market to Reach $18.9 billion by 2016 2New Forecast Shows Patient Monitoring Systems Market to Reach $18.9 billion by 2016 3Millstone Medical Outsourcing Hires New Vice President Quality 2
(Date:6/1/2015)... (PRWEB) June 01, 2015 Hexagon Geospatial ... which is a new cloud-based subscription service that provides ... GIS software. , Both ERDAS IMAGINE and ... through Producer Online, which offers a subscription model for ... organizations need to be able to quickly and easily ...
(Date:6/1/2015)... The session, entitled “Building the Blueprint ... president of Elektrobit Automotive Americas, senior representatives from ... will be moderated by Andy Gryc of CX3 Marketing. ... complexity of in-vehicle software in connected vehicles and autonomous ... how the wider ecosystem can fit into new vehicle ...
(Date:6/1/2015)... CA (PRWEB) June 01, 2015 This ... 2nd Annual GrowRIVERSIDE Conference: The Future of Local Food, ... The conference will assist cities in examining ... and urban agriculture infrastructure. , Organized for the city ... will feature a broad lineup of speakers ranging from ...
(Date:6/1/2015)... If you dread visiting a dentist because ... have some encouraging news. With an idea created by ... San Marcos, Calif., you no longer need to worry. ... Tip to provide improved oral suction needed for dental ... a dental patient’s throat more comfortable by removing excess ...
(Date:6/1/2015)... 01, 2015 Kurbo Health , which ... and teens, announced today it has added in-app chat ... kids and teens to eat smart and reach their healthier ... coaches via text message and phone or video calls, now ... their in-app chat window. For paid users, they will be ...
Breaking Medicine News(10 mins):Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 2Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 3Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 2Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 3Health News:Limited Tickets Available for “GrowRIVERSIDE” Conference June 11 2Health News:All-in-One Dental Aspirator Invented by InventHelp® Clients (SDB-733) 2Health News:Kurbo, First Mobile Weight Loss Program for Children and Teens, Enhances Coaching with New iOS In-App Chat and Messaging from Coaches 2
... of the hallucinogen psilocybin, the active ingredient in so-called ... personality change lasting at least a year in nearly ... study, according to the Johns Hopkins researchers who conducted ... of the personality known as openness, which includes traits ...
... , WEDNESDAY, Sept. 28 (HealthDay News) -- Cancer patients ... can have serious side effects and even mean the ... crucial that patients insist doctors use plain language ... associate professor of internal medicine at the University of ...
... a patient,s own stem cells, researchers at Johns Hopkins have ... a painful, disabling inherited blood disorder that affects mostly African-Americans. ... cells in a test tube that then turned on a ... cautions that the work, done only in the laboratory, is ...
... Researchers at the Stanford University School of Medicine have ... activation patterns in children with poor reading skills and ... readers with a typical IQ. The work provides more ... difficulties regardless of their general cognitive ability. Schools ...
... large-scale study on cat intestinal cancer has provided new insight ... could ultimately benefit humans. "We are looking for patterns ... risk factors," said Kim Selting, associate teaching professor of oncology ... former resident, Kerry Rissetto, as she examined intestinal tumors in ...
... at the University of California, San Francisco (UCSF) Medical Center ... occurs as healthy brain cells begin to form tumors. ... a common type of brain tumor, at its earliest stage, ... will have to prove safe and effective in clinical trials, ...
Cached Medicine News:Health News:Single dose of hallucinogen may create lasting personality change 2Health News:Single dose of hallucinogen may create lasting personality change 3Health News:Cancer Patients Should Ask Doctors to Use Simple Terms 2Health News:Correcting sickle cell disease with stem cells 2Health News:Stanford brain imaging study shows physiological basis of dyslexia 2Health News:Stanford brain imaging study shows physiological basis of dyslexia 3Health News:University of Missouri study finds risk factors for cat cancer, could have human implications 2Health News:How normal cells become brain cancers 2
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Form: Cream-colored powder Moisture: 10% Ash: 6.5% Gel Strength (1.5%): 550 950 gm/cm 2 Gel pH (1.5%): 6.0 7.5 Gel Point (1.5%): 34 38C Melting Point (1.5%): 84 88C Application: Bacterial ...
An agent used for making solid microbiological media....
... range of miniTHERM incubators is available, ensuring ... solution for their specific requirements. miniTHERM incubators ... compact and extremely space saving. Their size ... It is possible to stack up to ...
Medicine Products: